Join the Thyroid Cancer group to help and get support from people like you.
Thyroid Cancer News
Related terms: Anaplastic thyroid cancer
Air, Light Pollution May Increase Risk for Pediatric Papillary Thyroid Cancer
TUESDAY, April 22, 2025 – Early-life exposure to fine particulate matter (PM2.5) and outdoor artificial light at night (O-ALAN) is associated with pediatric papillary thyroid cancer, according to a...
Air, Light Pollution Increase Risk Of Thyroid Cancer In Children
FRIDAY, April 18, 2025 – Babies exposed to air and light pollution have a higher risk of developing childhood thyroid cancer, a new study says. Airborne particle pollution and outdoor artificial...
Overdiagnosis of Thyroid Cancer Persists
WEDNESDAY, Feb. 12, 2025 – Overdiagnosis of thyroid cancer in the United States remains a persistent problem, according to a study published online Feb. 5 in The Lancet Diabetes & Endocrinology....
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
THURSDAY, Jan. 30, 2025 – The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of...
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
WEDNESDAY, Jan. 22, 2025 – Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published ...
New Hope Against a Rare, Aggressive Form of Thyroid Cancer
MONDAY, Oct. 28, 2024 – Most thyroid cancers are slow-moving and, if caught early, curable. But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) – a rare and...
FDA Grants Traditional Approval to Retevmo (selpercatinib) for Medullary Thyroid Cancer with a RET Mutation
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with...
Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer
THURSDAY, Sept. 26, 2024 – Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other nonkeratinocyte skin cancers when limiting the...
Study Looks at Impact of Peritoneal Dialysis on Thyroid Function
MONDAY, Sept. 23, 2024 – Patients undergoing peritoneal dialysis (PD) have significantly higher thyroxine (T4) concentrations than hemodialysis (HD) patients and higher free T4 (FT4) concentrations...
FDA Grants Accelerated Approval to Retevmo (selpercatinib) for Pediatric Patients Two Years and Older with RET-Altered Metastatic Thyroid Cancer or Solid Tumors
On May 29, 2024, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following: ...
FDA Grants Traditional Approval for Retevmo (selpercatinib) for RET Fusion-Positive Thyroid Cancer
On June 12, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with...
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 17, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx® (cabozantinib) for the treatment ...
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
South San Francisco, CA – December 1, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), ...